NCT04003636 2026-03-24KEYNOTE-966Merck Sharp & Dohme LLCPhase 3 Completed1,069 enrolled 19 charts 2 FDA
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 9 FDA
NCT02924376 2025-08-14Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)Incyte CorporationPhase 2 Completed147 enrolled 22 charts 3 FDA
NCT02052778 2025-03-27A Study of TAS-120 in Patients With Advanced Solid TumorsTaiho Oncology, Inc.Phase 1/2 Completed407 enrolled 45 charts 2 FDA
NCT02150967 2023-07-03A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaQED Therapeutics, a BridgeBio companyPhase 2 Terminated143 enrolled 25 charts 2 FDA